{"url_path":"/sec/mbrx/8-k/2026-06-30/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-022087-index.html","accession_number":"0001437749-26-022087","cik":"0001659617","ticker":"MBRX","issuer_name":"Moleculin Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-022087-index.html","primary_entity_key":"0001659617","primary_entity_name":"Moleculin Biotech, Inc."},"word_count":57,"has_tables":true,"body_markdown":"**Item 8.01**\n\n**Other Events**\n\n \n\nSubsequent to the filing on May 14, 2026 of the Company's Form 10-Q for the period ended March 31, 2026, warrants to purchase 1,361,500 shares of Company common stock have been exercised for gross proceeds of approximately $2.7 million. As of June 29, 2026, the Company had 7,065,000 shares of common stock outstanding."}